US20220218529A1 - Reduced pressure device having selectively deliverable electrolyte - Google Patents
Reduced pressure device having selectively deliverable electrolyte Download PDFInfo
- Publication number
- US20220218529A1 US20220218529A1 US17/709,561 US202217709561A US2022218529A1 US 20220218529 A1 US20220218529 A1 US 20220218529A1 US 202217709561 A US202217709561 A US 202217709561A US 2022218529 A1 US2022218529 A1 US 2022218529A1
- Authority
- US
- United States
- Prior art keywords
- reduced pressure
- dressing
- pressure device
- electrolyte solution
- reducing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003792 electrolyte Substances 0.000 title 1
- 239000008151 electrolyte solution Substances 0.000 claims abstract description 51
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 49
- 239000000126 substance Substances 0.000 claims description 37
- 239000002775 capsule Substances 0.000 claims description 26
- 239000000758 substrate Substances 0.000 claims description 19
- 239000000853 adhesive Substances 0.000 claims description 10
- 230000001070 adhesive effect Effects 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 239000007789 gas Substances 0.000 description 21
- 239000010409 thin film Substances 0.000 description 18
- 230000002745 absorbent Effects 0.000 description 13
- 239000002250 absorbent Substances 0.000 description 13
- 238000007789 sealing Methods 0.000 description 13
- 206010052428 Wound Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000009581 negative-pressure wound therapy Methods 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- -1 e.g. Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000013536 elastomeric material Substances 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 239000004447 silicone coating Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A61F13/05—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00068—Accessories for dressings specially adapted for application or removal of fluid, e.g. irrigation or drainage of wounds, under-pressure wound-therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/73—Suction drainage systems comprising sensors or indicators for physical values
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/80—Suction pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/96—Suction control thereof
- A61M1/962—Suction control thereof having pumping means on the suction site, e.g. miniature pump on dressing or dressing capable of exerting suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/98—Containers specifically adapted for negative pressure wound therapy
- A61M1/984—Containers specifically adapted for negative pressure wound therapy portable on the body
- A61M1/985—Containers specifically adapted for negative pressure wound therapy portable on the body the dressing itself forming the collection container
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00119—Wound bandages elastic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
Definitions
- Negative pressure and reduced pressure are terms used to describe a pressure that is below normal atmospheric pressure.
- Negative pressure wound therapy (“NPWT”) is utilized for several sites on the skin, such as a wound or an incision. Furthermore, NPWT is useful to manage wounds with complex healing concerns.
- Negative or reduced pressure therapy may also be used for a therapeutic treatment that utilizes negative pressure for skin treatments and restorative purposes.
- the pressure used for skin treatments and restorative purposes may not need to be as low (offset from normal atmospheric pressure) as that used in NPWT.
- the pressure may need to be reduced to only ⁇ 20 mmHg or ⁇ 40 mmHg.
- simply a reduced pressure may be desired in some instances, even including instances where a wound may be treated.
- a vacuum generation source such as an electromechanical pump
- a vacuum source operates using a chemical reaction in which a gas found in air is consumed to as to reduce the pressure at the dressing site
- a substrate impregnated with a reducing agent and an electrolyte solution from air using an air-tight foil packet.
- the substrate is exposed to air by tearing or removing a section of the air-tight foil packet.
- other manners to activate the chemical reaction may be desirable.
- a reduced pressure device includes a dressing and a reactor.
- the dressing covers a dressing site and defines an enclosed volume beneath the dressing and around the dressing site.
- the reactor is disposed with respect to the dressing so as to produce a reduced pressure beneath the dressing when activated.
- the reactor includes a reducing agent and an electrolyte solution.
- the electrolyte solution is configured to be selectively delivered to the reducing agent, and the reactor begins to react with at least one selected gas in the enclosed volume after the electrolyte solution is delivered to the reducing agent to consume the at least one selected gas within the enclosed volume.
- FIG. 1 is a schematic cross-sectional view of a reduced pressure device.
- FIG. 2 is a schematic cross-sectional view of the reduced pressure device according to an alternative arrangement.
- FIG. 3 is schematic cross-sectional view of a reduced pressure device after rupturing a capsule.
- FIG. 4 is a schematic cross-sectional view of another reduced pressure device.
- FIG. 5 is a schematic cross-sectional view of another reduced pressure device.
- FIG. 6 is a schematic cross-sectional view of another reduced pressure device.
- FIG. 7 is a perspective view of a dressing connected with a chemical pump housing.
- FIG. 8 is a schematic cross-sectional view of the chemical pump housing.
- FIG. 9 is a schematic cross-sectional view of an alternative chemical pump housing.
- FIG. 10 is a schematic cross-sectional view of an alternative chemical pump housing.
- FIG. 1 depicts a reduced pressure device 10 useful for administering negative and/or reduced pressure therapy to a dressing site 12 .
- Reduced pressure described herein is pressure below atmospheric pressure.
- the reduced pressure device 10 includes a dressing 14 and a reactor 16 , which operates as a vacuum source.
- the dressing 14 is placed over the dressing site 12 on a patient's skin S.
- the dressing site 12 can be, but is not limited to, a wound, an incision, or skin where there is no wound or incision, for example in a cosmetic application.
- the reduced pressure device 10 which can be used for NPWT or for instances where the pressure need not be reduced to what is typically achieved in NPWT, generally includes the dressing 14 , the reactor 16 , a drape 20 , an absorbent element 22 , and a sealing element 24 .
- the dressing 14 may further include valves, pressure indicators and the like.
- the drape 20 can be made from a flexible material and can be a thin film capable of maintaining a reduced pressure underneath the drape 20 upon application of a vacuum.
- the thin film from which the drape 20 is made can be substantially impermeable to liquids but somewhat permeable to water vapor, while still being capable of maintaining reduced pressure underneath the drape 20 .
- the thin film material from which the drape 20 is made may be constructed of polyurethane or other semi-permeable material such as that sold under the Tegaderm® brand or 9834 TPU tape available from 3M. Similar films are also available from other manufacturers.
- the drape 20 can be made in a variety of shapes and sizes to cover a variety of dressing sites 12 .
- the absorbent element 22 is made from an absorbent material that is capable of absorbing exudate from the dressing site 12 .
- the absorbent element 22 can be made from super absorbent acrylate, absorbent beads, foams, or natural absorbents.
- the absorbent element 22 can also be a hydroactive wound pad available under the trademark Vilmed®, which chemically absorbs exudate and precludes the exudate from passing through the absorbent element 22 toward the reactor 16 unlike a sponge.
- the sealing element 24 cooperates with the drape 20 and skin S to create an enclosed volume 32 defined between the drape 20 and the dressing site 12 and surrounded by the sealing element 24 .
- the reactor 16 which when activated operates as a vacuum source in fluid communication with the enclosed volume 32 , administers reduced pressure to the enclosed volume 32 so as to control the atmosphere within the enclosed volume 32 .
- the sealing element 24 can be separate from the dressing 14 or can instead be a component of the dressing 14 .
- the sealing element 24 functions like a gasket, as the sealing element 24 prevents fluid (including air) from escaping between the drape 20 and the skin S.
- the sealing element 24 can be made from a material such as silicone or a hydrogel material, for example.
- the dressing 14 may further include a wound contact layer 36 .
- the wound contact layer 36 can be made of an elastomeric material, such as a polymeric material that has rubber-like properties.
- the wound contact layer 36 can be an elastomeric material that is a thin, flexible elastomeric film. Some examples of such materials include a silver coated nylon, a perforated silicone mesh, or other material that will not stick to the patient's tissue.
- the wound contact layer 36 can also be a polyurethane film layer in which holes can be provided. A silicone coating can also be provided on a skin-contacting side of the absorbent element 22 instead of the wound contact layer 36 .
- a drape release liner (not shown in FIG. 1 ) is disposed on a bottom surface of the drape 20 .
- the drape release liner is removed before the dressing 14 is applied to the dressing site 12 .
- an adhesive 38 on the bottom surface of the drape 20 is exposed.
- the adhesive 38 which can be an acrylic-based adhesive that is distinct from the sealing element 24 , secures the drape 30 to the patient's skin S around the dressing site 12 . Thus, contact is maintained between the drape 20 and the skin S.
- the dressing 14 may also include a membrane 40 between the reactor 16 and the absorbent element 22 .
- the membrane 40 which can be a thin film similar to the drape 20 , is fixed to the bottom surface of the drape 20 .
- the membrane 40 includes at least one opening 42 or is pervious to air so that air is allowed to travel through the membrane 40 . Therefore, the reactor 16 is in fluid communication with the enclosed volume 32 .
- the membrane 40 can disposed over the dressing site 12 with the absorbent element 22 affixed to it.
- the dressing 14 can be what may be referred to as a two-piece dressing in which the membrane 40 and the absorbent element 22 are placed on the patient's skin S over the dressing site 12 , and then the drape 20 and the components affixed thereto are placed over the membrane 40 and the dressing site 12 .
- the membrane 40 would include an adhesive on a lower surface to allow the membrane to adhere to the skin S.
- the membrane 40 may also include a sealing element (similar to the sealing element 24 ) which would allow the drape 20 to be adhered and sealed to the membrane 40 instead of the skin S.
- the reactor 16 is configured to react with at least one selected gas found in air to remove the selected gas from air.
- the reactor 16 is located with respect to the drape 20 and the sealing element 24 so that the reactor 16 can be in fluid communication with the enclosed volume 32 .
- the reactor 16 consumes the selected gas from the enclosed volume 32 thereby removing the selected gas and reducing the gas pressure.
- the reactor 16 can be an oxygen scavenger which removes oxygen from the air within the enclosed volume 32 so as to reduce gas pressure within the enclosed volume 32 by approximately 20%. Since the vacuum source in this embodiment is the reactor 16 that consumes a gas found in air (as opposed to a mechanical pump), any leakage around the enclosed volume 32 is important to prevent. Uncontrolled ingress of outside oxygen, which could prematurely use up the reactor 16 , should be prevented or limited from penetrating either through the drape 20 or the sealing element 24 or between the sealing element 24 and the skin S.
- the reactor 16 includes a reducing agent 50 , such as aluminum, zinc or iron, and an electrolyte solution 52 .
- a reducing agent 50 such as aluminum, zinc or iron
- an electrolyte solution 52 An example of a substrate impregnated with a reducing agent and an electrolyte solution is found in U.S. Publication No. 2014/0109890A1.
- the electrolyte solution 52 is shielded from the reducing agent 50 until reduced pressure beneath the dressing 14 is ready to be administered obviating the need for the hermetically sealed foil package.
- the electrolyte solution 52 is introduced to the reducing agent 50 .
- the reactor 16 then begins to react with the at least one selected gas, e.g., oxygen, in the enclosed volume 32 to create reduced pressure at the dressing site 12 .
- the dressing 14 may further include a substrate 54 that includes the reducing agent 50 and a binding agent, such as polytetrafluoroethylene or a polyolefin.
- a binding agent such as polytetrafluoroethylene or a polyolefin.
- substrate means that the substrate 54 is a solid object, and not merely a mass of powdered chemicals; however, the reducing agent 50 could be provided in the dressing 14 as a mass of powdered chemicals, if desired.
- the electrolyte solution 52 is stored in a rupturable capsule 56 disposed adjacent to the reducing agent 50 .
- the capsule 56 can be any package that can be selectively ruptured to allow liquid contents disposed therein to leak from the package after it is ruptured.
- the user presses onto a pressing location 58 on the drape 20 over the capsule 56 to break the capsule 56 .
- the electrolyte solution 52 is delivered to the reducing agent 50 , and the reducing agent 50 begins to react with the at least one selected gas in the enclosed volume 32 so as to consume the selected gas from the enclosed volume 32 .
- the drape 20 may include a marking 62 disposed on a top surface of the drape 20 above the capsule 56 to indicate where the pressing location 58 is located to provide an indication to a user of the pressing location 58 .
- the marking 62 may be a circle disposed around a periphery of the pressing location 58 ; however, the marking 62 can be any marking that indicates to a user where the pressing location 58 is located.
- a button may also be provided at the pressing location 58 .
- an opening which is in the form of a slit 70 in the illustrated embodiment, is disposed on the drape 20 .
- a first pull tab 74 extends from beneath the drape 20 to ambient through the slit 70 and is connected to a separable layer 76 of the capsule 56 .
- the separable layer 76 isolates the electrolyte solution 52 within the capsule 56 and from the reducing agent 50 .
- the first pull tab 74 which could also be in the form of a string, can be pulled to remove the first pull tab 74 and the separable layer 76 from the slit 70 .
- the separable layer 76 is removed from the capsule 56 and, if desired, from the enclosed volume 32 through the slit 70 , exposing the reducing agent 50 to the electrolyte solution 52 .
- the electrolyte solution 52 is delivered to the reducing agent 50 , which begins to react with a selected gas, e.g., oxygen, in the enclosed volume 32 .
- a second pull tab 78 is connected to a cover layer, which can be a thin film 82 placed over and adhered to a portion of the top surface of the drape 20 .
- the thin film 82 could be made integral with the drape 20 .
- the thin film 82 can include a flap 84 and, as depicted in FIG. 4 , the slit 70 is disposed underneath the flap 84 .
- the second pull tab 78 can be connected to or provided as a release layer provided on a bottom surface of the thin film 82 in the region of the flap 84 .
- the release layer covers an adhesive (not visible in FIG. 4 ) on a bottom surface of the thin film 82 .
- the second pull tab 78 When the second pull tab 78 is pulled, which occurs after the first pull tab 74 has been removed from the slit 70 , the second pull tab 78 disconnects the release layer from the flap 84 and the adhesive disposed on the bottom surface of the flap 84 is exposed. The flap 84 is then moved towards the drape 20 to cover the slit 70 . When the thin film 82 covers the slit 70 , the reactor 16 is closed off from ambient and reacts with the selected gas found in the enclosed volume 32 under the dressing 14 . Reduced pressure is therefore developed in the enclosed volume 32 .
- the electrolyte solution 52 can be injected into the dressing 14 when reduced pressure therapy is ready to be administered.
- the electrolyte solution 52 can be injected into the substrate 54 having the reducing agent 50 or into a mass of powdered chemicals making up the reducing agent 50 by a syringe 90 .
- An injection port 92 can be disposed on the drape 20 for guiding a user for injecting a needle 94 of the syringe 90 into the substrate 54 or mass of powdered chemicals making up the reducing agent 50 .
- the user injects the electrolyte solution 52 into the substrate 54 to impregnate the substrate 54 with the electrolyte solution 52 or into the mass of powdered chemicals making up the reducing agent 50 .
- the reactor 16 begins to react with the selected gas in the enclosed volume 32 and consuming the selected gas.
- the injection port 92 can be covered with a thin film in a similar manner to the slit 70 shown in FIG. 4 .
- the electrolyte solution 52 can be stored in a flexible chamber 130 until the reduced pressure therapy is ready to be administered.
- the flexible chamber 130 can be located externally from the dressing 14 .
- the flexible chamber 130 is connected to the substrate 54 having the reducing agent 50 or the mass of powdered chemicals making up the reducing agent 50 by a flow conduit 132 .
- the flow conduit 132 can further include a seal 138 .
- the seal 138 can be located at any portion of the flow conduit 132 .
- the flexible chamber 130 When reduced pressure therapy is to be administered, the flexible chamber 130 is pressed and/or squeezed and the flow pressure of the electrolyte solution 52 breaks the seal 138 , and the electrolyte solution 52 is delivered to the substrate 54 or the mass of powdered chemicals making up the reducing agent 50 .
- FIG. 7 depicts an example in which the reactor 16 is positioned outside of the dressing 14 while still being positioned with respect to the dressing 14 so as to produce a reduced pressure beneath the dressing 14 when activated.
- the reactor 16 is positioned within a chemical pump housing 150 .
- the chemical pump housing 150 can either connect directly to a fitting 152 provided on the dressing 14 via a fitting or valve 154 ( FIG. 8 ) on the chemical pump housing 150 or can connect via a hose (not shown) to the dressing 14 via the fitting 152 or something similar.
- an inner chamber 156 of the chemical pump housing 150 is in fluid communication with the enclosed volume 32 .
- a flexible section or button 160 can be disposed on a surface of the chemical pump housing 150 .
- the flexible section or button 160 is preferably disposed on a top surface of the chemical pump housing 150 .
- the flexible section or button 160 can be aligned with the capsule 56 so as to be a pressing location where a user can press to break the capsule 56 containing the electrolyte solution 52 .
- the electrolyte solution 52 is delivered to the substrate 54 or mass of powdered chemicals making up the reducing agent 50 . Similar to that described above, after the reducing agent 50 is wetted with the electrolyte solution 52 , the reactor 16 begins to consume the selected gas in the enclosed volume 32 and the inner chamber 156 .
- a slit 170 is disposed on the chemical pump housing 150 instead of the dressing 14 .
- a first pull tab 174 extends from the inner chamber 156 to ambient and is connected to a separable layer 176 of the capsule 56 .
- the separable layer 176 isolates the electrolyte solution 52 within the capsule 56 and from the reducing agent 50 .
- the first pull tab 174 which could also be in the form of a string, can be pulled to remove the first pull tab 174 and the separable layer 176 from the slit 170 .
- the separable layer 176 is removed from the capsule 56 and, if desired, from the inner chamber 156 through the slit 170 , exposing the reducing agent 50 to the electrolyte solution 52 .
- the electrolyte solution 52 is delivered to the reducing agent 50 , which begins to react with a selected gas, e.g., oxygen, in the inner chamber 156 and the enclosed volume 32 .
- a cover layer which can be a thin film 182 , is disposed on the chemical pump housing 150 .
- a second pull tab 178 is connected to the thin film 82 , which is placed over and adhered to a portion of the top surface of the chemical pump housing 150 .
- the thin film 182 includes a flap 184 and, as depicted in FIG. 9 , the slit 170 is disposed underneath the flap 184 .
- the second pull tab 178 can be connected to or provided as a release layer provided on a bottom surface of the thin film 182 in the region of the flap 184 .
- the release layer covers an adhesive (not visible in FIG. 9 ) on a bottom surface of the thin film 182 .
- the second pull tab 178 When the second pull tab 178 is pulled, which occurs after the first pull tab 174 has been removed from the slit 170 , the second pull tab 178 disconnects the release layer from the flap 184 and the adhesive disposed on the bottom surface of the flap 184 is exposed. The flap 184 is then moved towards the chemical pump housing 150 to cover the slit 170 . When the thin film 182 covers the slit 170 , the reactor 116 is closed off from ambient and reacts with the selected gas found in the inner chamber 156 and the enclosed volume 32 under the dressing 14 . Reduced pressure is therefore developed in the enclosed volume 32 .
- the electrolyte solution 52 can be injected into the substrate 54 or mass of powdered chemicals making up the reducing agent 50 through the chemical pump housing 150 when reduced pressure therapy is ready to be administered.
- An injection port 192 can be disposed on the chemical pump housing 150 for guiding a user for injecting the needle 94 of the syringe 90 into the substrate 54 or mass of powdered chemicals making up the reducing agent 50 .
- the user injects the electrolyte solution 52 into the substrate 54 to impregnate the substrate 54 with the electrolyte solution 52 or into the mass of powdered chemicals making up the reducing agent 50 .
- the reactor 16 begins to consume the selected gas in the enclosed volume 32 and the inner chamber 156 of the chemical pump housing 150 .
- the injection port 92 can be covered with the thin film 182 and the flap 184 in a similar manner to the slit 170 shown in FIG. 9 .
- the electrolyte solution 52 stored in the flexible chamber 130 shown in FIG. 6 can deliver the electrolyte solution 52 through the injection port 192 in the chemical pump housing 150 similar to the syringe 90 .
Abstract
Description
- Negative pressure and reduced pressure are terms used to describe a pressure that is below normal atmospheric pressure. Negative pressure wound therapy (“NPWT”) is utilized for several sites on the skin, such as a wound or an incision. Furthermore, NPWT is useful to manage wounds with complex healing concerns.
- Negative or reduced pressure therapy may also be used for a therapeutic treatment that utilizes negative pressure for skin treatments and restorative purposes. In these instances the pressure used for skin treatments and restorative purposes may not need to be as low (offset from normal atmospheric pressure) as that used in NPWT. For example, where −80 mmHg to −125 or even −150 mmHg may be desired for NPWT, for skin treatments and restorative purposes the pressure may need to be reduced to only −20 mmHg or −40 mmHg. As such, simply a reduced pressure may be desired in some instances, even including instances where a wound may be treated.
- It is known to use a vacuum generation source, such as an electromechanical pump, to apply reduced pressure to the inside of a dressing on a dressing site. However, when a vacuum source operates using a chemical reaction in which a gas found in air is consumed to as to reduce the pressure at the dressing site, it is known to isolate a substrate impregnated with a reducing agent and an electrolyte solution from air using an air-tight foil packet. When it is desired to begin the chemical reaction, the substrate is exposed to air by tearing or removing a section of the air-tight foil packet. However, other manners to activate the chemical reaction may be desirable.
- In view of the foregoing, a reduced pressure device includes a dressing and a reactor. The dressing covers a dressing site and defines an enclosed volume beneath the dressing and around the dressing site. The reactor is disposed with respect to the dressing so as to produce a reduced pressure beneath the dressing when activated. The reactor includes a reducing agent and an electrolyte solution. The electrolyte solution is configured to be selectively delivered to the reducing agent, and the reactor begins to react with at least one selected gas in the enclosed volume after the electrolyte solution is delivered to the reducing agent to consume the at least one selected gas within the enclosed volume.
-
FIG. 1 is a schematic cross-sectional view of a reduced pressure device. -
FIG. 2 is a schematic cross-sectional view of the reduced pressure device according to an alternative arrangement. -
FIG. 3 is schematic cross-sectional view of a reduced pressure device after rupturing a capsule. -
FIG. 4 is a schematic cross-sectional view of another reduced pressure device. -
FIG. 5 is a schematic cross-sectional view of another reduced pressure device. -
FIG. 6 is a schematic cross-sectional view of another reduced pressure device. -
FIG. 7 is a perspective view of a dressing connected with a chemical pump housing. -
FIG. 8 is a schematic cross-sectional view of the chemical pump housing. -
FIG. 9 is a schematic cross-sectional view of an alternative chemical pump housing. -
FIG. 10 is a schematic cross-sectional view of an alternative chemical pump housing. -
FIG. 1 depicts a reducedpressure device 10 useful for administering negative and/or reduced pressure therapy to adressing site 12. Reduced pressure described herein is pressure below atmospheric pressure. The reducedpressure device 10 includes adressing 14 and areactor 16, which operates as a vacuum source. Thedressing 14 is placed over thedressing site 12 on a patient's skin S. Thedressing site 12 can be, but is not limited to, a wound, an incision, or skin where there is no wound or incision, for example in a cosmetic application. The reducedpressure device 10, which can be used for NPWT or for instances where the pressure need not be reduced to what is typically achieved in NPWT, generally includes thedressing 14, thereactor 16, adrape 20, anabsorbent element 22, and asealing element 24. Thedressing 14 may further include valves, pressure indicators and the like. - The
drape 20 can be made from a flexible material and can be a thin film capable of maintaining a reduced pressure underneath thedrape 20 upon application of a vacuum. The thin film from which thedrape 20 is made can be substantially impermeable to liquids but somewhat permeable to water vapor, while still being capable of maintaining reduced pressure underneath thedrape 20. For example, the thin film material from which thedrape 20 is made may be constructed of polyurethane or other semi-permeable material such as that sold under the Tegaderm® brand or 9834 TPU tape available from 3M. Similar films are also available from other manufacturers. Thedrape 20 can be made in a variety of shapes and sizes to cover a variety ofdressing sites 12. - The
absorbent element 22 is made from an absorbent material that is capable of absorbing exudate from thedressing site 12. Theabsorbent element 22 can be made from super absorbent acrylate, absorbent beads, foams, or natural absorbents. Theabsorbent element 22 can also be a hydroactive wound pad available under the trademark Vilmed®, which chemically absorbs exudate and precludes the exudate from passing through theabsorbent element 22 toward thereactor 16 unlike a sponge. - The sealing
element 24 cooperates with thedrape 20 and skin S to create an enclosedvolume 32 defined between thedrape 20 and thedressing site 12 and surrounded by thesealing element 24. Thereactor 16, which when activated operates as a vacuum source in fluid communication with the enclosedvolume 32, administers reduced pressure to the enclosedvolume 32 so as to control the atmosphere within the enclosedvolume 32. Thesealing element 24 can be separate from thedressing 14 or can instead be a component of thedressing 14. The sealingelement 24 functions like a gasket, as thesealing element 24 prevents fluid (including air) from escaping between thedrape 20 and the skin S. The sealingelement 24 can be made from a material such as silicone or a hydrogel material, for example. - The
dressing 14 may further include awound contact layer 36. Thewound contact layer 36 can be made of an elastomeric material, such as a polymeric material that has rubber-like properties. Furthermore, thewound contact layer 36 can be an elastomeric material that is a thin, flexible elastomeric film. Some examples of such materials include a silver coated nylon, a perforated silicone mesh, or other material that will not stick to the patient's tissue. Thewound contact layer 36 can also be a polyurethane film layer in which holes can be provided. A silicone coating can also be provided on a skin-contacting side of theabsorbent element 22 instead of thewound contact layer 36. - A drape release liner (not shown in
FIG. 1 ) is disposed on a bottom surface of thedrape 20. The drape release liner is removed before thedressing 14 is applied to thedressing site 12. When the drape release liner is removed, an adhesive 38 on the bottom surface of thedrape 20 is exposed. As thedressing 14 is placed on the patient, theadhesive 38, which can be an acrylic-based adhesive that is distinct from thesealing element 24, secures the drape 30 to the patient's skin S around thedressing site 12. Thus, contact is maintained between thedrape 20 and the skin S. - The
dressing 14 may also include amembrane 40 between thereactor 16 and theabsorbent element 22. In the embodiment shown inFIG. 1 , themembrane 40, which can be a thin film similar to thedrape 20, is fixed to the bottom surface of thedrape 20. Themembrane 40 includes at least one opening 42 or is pervious to air so that air is allowed to travel through themembrane 40. Therefore, thereactor 16 is in fluid communication with the enclosedvolume 32. In an alternative embodiment shown inFIG. 2 , themembrane 40 can disposed over thedressing site 12 with theabsorbent element 22 affixed to it. In this alternative embodiment, the dressing 14 can be what may be referred to as a two-piece dressing in which themembrane 40 and theabsorbent element 22 are placed on the patient's skin S over thedressing site 12, and then thedrape 20 and the components affixed thereto are placed over themembrane 40 and thedressing site 12. In the embodiment depicted inFIG. 2 , themembrane 40 would include an adhesive on a lower surface to allow the membrane to adhere to the skin S. Themembrane 40 may also include a sealing element (similar to the sealing element 24) which would allow thedrape 20 to be adhered and sealed to themembrane 40 instead of the skin S. - The
reactor 16 is configured to react with at least one selected gas found in air to remove the selected gas from air. Thereactor 16 is located with respect to thedrape 20 and the sealingelement 24 so that thereactor 16 can be in fluid communication with theenclosed volume 32. Thereactor 16 consumes the selected gas from the enclosedvolume 32 thereby removing the selected gas and reducing the gas pressure. For example, thereactor 16 can be an oxygen scavenger which removes oxygen from the air within theenclosed volume 32 so as to reduce gas pressure within theenclosed volume 32 by approximately 20%. Since the vacuum source in this embodiment is thereactor 16 that consumes a gas found in air (as opposed to a mechanical pump), any leakage around theenclosed volume 32 is important to prevent. Uncontrolled ingress of outside oxygen, which could prematurely use up thereactor 16, should be prevented or limited from penetrating either through thedrape 20 or the sealingelement 24 or between the sealingelement 24 and the skin S. - The
reactor 16 includes a reducingagent 50, such as aluminum, zinc or iron, and anelectrolyte solution 52. An example of a substrate impregnated with a reducing agent and an electrolyte solution is found in U.S. Publication No. 2014/0109890A1. Unlike the heater described in U.S. Publication No. 2014/0109890A1 in which a substrate having the reducing agent and a pad impregnated with the electrolyte solution are packaged in a hermetically sealed foil package, theelectrolyte solution 52 is shielded from the reducingagent 50 until reduced pressure beneath the dressing 14 is ready to be administered obviating the need for the hermetically sealed foil package. When reduced pressure therapy is ready to be administered to the dressing 14, theelectrolyte solution 52 is introduced to the reducingagent 50. Thereactor 16 then begins to react with the at least one selected gas, e.g., oxygen, in theenclosed volume 32 to create reduced pressure at thedressing site 12. As illustrated inFIG. 1 , the dressing 14 may further include asubstrate 54 that includes the reducingagent 50 and a binding agent, such as polytetrafluoroethylene or a polyolefin. The term “substrate” means that thesubstrate 54 is a solid object, and not merely a mass of powdered chemicals; however, the reducingagent 50 could be provided in the dressing 14 as a mass of powdered chemicals, if desired. - In
FIG. 1 , theelectrolyte solution 52 is stored in arupturable capsule 56 disposed adjacent to the reducingagent 50. Thecapsule 56 can be any package that can be selectively ruptured to allow liquid contents disposed therein to leak from the package after it is ruptured. The user presses onto apressing location 58 on thedrape 20 over thecapsule 56 to break thecapsule 56. Once thecapsule 56 is broken, which is shown inFIG. 3 , theelectrolyte solution 52 is delivered to the reducingagent 50, and the reducingagent 50 begins to react with the at least one selected gas in theenclosed volume 32 so as to consume the selected gas from the enclosedvolume 32. Thedrape 20 may include a marking 62 disposed on a top surface of thedrape 20 above thecapsule 56 to indicate where thepressing location 58 is located to provide an indication to a user of thepressing location 58. The marking 62 may be a circle disposed around a periphery of thepressing location 58; however, the marking 62 can be any marking that indicates to a user where thepressing location 58 is located. A button may also be provided at thepressing location 58. - With reference to
FIG. 4 , in another embodiment, an opening, which is in the form of aslit 70 in the illustrated embodiment, is disposed on thedrape 20. Afirst pull tab 74 extends from beneath thedrape 20 to ambient through theslit 70 and is connected to aseparable layer 76 of thecapsule 56. Theseparable layer 76 isolates theelectrolyte solution 52 within thecapsule 56 and from the reducingagent 50. Thefirst pull tab 74, which could also be in the form of a string, can be pulled to remove thefirst pull tab 74 and theseparable layer 76 from theslit 70. When thefirst pull tab 74 is pulled, theseparable layer 76 is removed from thecapsule 56 and, if desired, from the enclosedvolume 32 through theslit 70, exposing the reducingagent 50 to theelectrolyte solution 52. After the removal of theseparable layer 76, theelectrolyte solution 52 is delivered to the reducingagent 50, which begins to react with a selected gas, e.g., oxygen, in theenclosed volume 32. - A
second pull tab 78 is connected to a cover layer, which can be athin film 82 placed over and adhered to a portion of the top surface of thedrape 20. Thethin film 82 could be made integral with thedrape 20. Thethin film 82 can include aflap 84 and, as depicted inFIG. 4 , theslit 70 is disposed underneath theflap 84. Thesecond pull tab 78 can be connected to or provided as a release layer provided on a bottom surface of thethin film 82 in the region of theflap 84. The release layer covers an adhesive (not visible inFIG. 4 ) on a bottom surface of thethin film 82. When thesecond pull tab 78 is pulled, which occurs after thefirst pull tab 74 has been removed from theslit 70, thesecond pull tab 78 disconnects the release layer from theflap 84 and the adhesive disposed on the bottom surface of theflap 84 is exposed. Theflap 84 is then moved towards thedrape 20 to cover theslit 70. When thethin film 82 covers theslit 70, thereactor 16 is closed off from ambient and reacts with the selected gas found in theenclosed volume 32 under the dressing 14. Reduced pressure is therefore developed in theenclosed volume 32. - Referring to
FIG. 5 , theelectrolyte solution 52 can be injected into the dressing 14 when reduced pressure therapy is ready to be administered. For example, theelectrolyte solution 52 can be injected into thesubstrate 54 having the reducingagent 50 or into a mass of powdered chemicals making up the reducingagent 50 by asyringe 90. Aninjection port 92 can be disposed on thedrape 20 for guiding a user for injecting aneedle 94 of thesyringe 90 into thesubstrate 54 or mass of powdered chemicals making up the reducingagent 50. When reduced pressure is ready to be administered, the user injects theelectrolyte solution 52 into thesubstrate 54 to impregnate thesubstrate 54 with theelectrolyte solution 52 or into the mass of powdered chemicals making up the reducingagent 50. Once the reducingagent 50 is wetted with theelectrolyte solution 52, thereactor 16 begins to react with the selected gas in theenclosed volume 32 and consuming the selected gas. After finishing injecting theelectrolyte solution 52 into the dressing 14, theinjection port 92 can be covered with a thin film in a similar manner to theslit 70 shown inFIG. 4 . - In yet another embodiment, with reference to
FIG. 6 , theelectrolyte solution 52 can be stored in aflexible chamber 130 until the reduced pressure therapy is ready to be administered. Theflexible chamber 130 can be located externally from the dressing 14. Theflexible chamber 130 is connected to thesubstrate 54 having the reducingagent 50 or the mass of powdered chemicals making up the reducingagent 50 by aflow conduit 132. Theflow conduit 132 can further include aseal 138. Theseal 138 can be located at any portion of theflow conduit 132. When reduced pressure therapy is to be administered, theflexible chamber 130 is pressed and/or squeezed and the flow pressure of theelectrolyte solution 52 breaks theseal 138, and theelectrolyte solution 52 is delivered to thesubstrate 54 or the mass of powdered chemicals making up the reducingagent 50. -
FIG. 7 depicts an example in which thereactor 16 is positioned outside of the dressing 14 while still being positioned with respect to the dressing 14 so as to produce a reduced pressure beneath the dressing 14 when activated. Thereactor 16 is positioned within achemical pump housing 150. Thechemical pump housing 150 can either connect directly to a fitting 152 provided on the dressing 14 via a fitting or valve 154 (FIG. 8 ) on thechemical pump housing 150 or can connect via a hose (not shown) to the dressing 14 via the fitting 152 or something similar. When properly connected with the dressing 14, aninner chamber 156 of thechemical pump housing 150 is in fluid communication with theenclosed volume 32. - Where the
chemical pump housing 150 is made from a rigid plastic, a flexible section orbutton 160 can be disposed on a surface of thechemical pump housing 150. The flexible section orbutton 160 is preferably disposed on a top surface of thechemical pump housing 150. The flexible section orbutton 160 can be aligned with thecapsule 56 so as to be a pressing location where a user can press to break thecapsule 56 containing theelectrolyte solution 52. After thecapsule 56 is ruptured, theelectrolyte solution 52 is delivered to thesubstrate 54 or mass of powdered chemicals making up the reducingagent 50. Similar to that described above, after the reducingagent 50 is wetted with theelectrolyte solution 52, thereactor 16 begins to consume the selected gas in theenclosed volume 32 and theinner chamber 156. - With reference to
FIG. 9 , aslit 170 is disposed on thechemical pump housing 150 instead of the dressing 14. When theslit 170 is disposed on thechemical pump housing 150, afirst pull tab 174 extends from theinner chamber 156 to ambient and is connected to aseparable layer 176 of thecapsule 56. Theseparable layer 176 isolates theelectrolyte solution 52 within thecapsule 56 and from the reducingagent 50. Thefirst pull tab 174, which could also be in the form of a string, can be pulled to remove thefirst pull tab 174 and theseparable layer 176 from theslit 170. When thefirst pull tab 174 is pulled, theseparable layer 176 is removed from thecapsule 56 and, if desired, from theinner chamber 156 through theslit 170, exposing the reducingagent 50 to theelectrolyte solution 52. After the removal of theseparable layer 176, theelectrolyte solution 52 is delivered to the reducingagent 50, which begins to react with a selected gas, e.g., oxygen, in theinner chamber 156 and theenclosed volume 32. - Also, a cover layer, which can be a
thin film 182, is disposed on thechemical pump housing 150. Asecond pull tab 178 is connected to thethin film 82, which is placed over and adhered to a portion of the top surface of thechemical pump housing 150. Thethin film 182 includes aflap 184 and, as depicted inFIG. 9 , theslit 170 is disposed underneath theflap 184. Thesecond pull tab 178 can be connected to or provided as a release layer provided on a bottom surface of thethin film 182 in the region of theflap 184. The release layer covers an adhesive (not visible inFIG. 9 ) on a bottom surface of thethin film 182. When thesecond pull tab 178 is pulled, which occurs after thefirst pull tab 174 has been removed from theslit 170, thesecond pull tab 178 disconnects the release layer from theflap 184 and the adhesive disposed on the bottom surface of theflap 184 is exposed. Theflap 184 is then moved towards thechemical pump housing 150 to cover theslit 170. When thethin film 182 covers theslit 170, the reactor 116 is closed off from ambient and reacts with the selected gas found in theinner chamber 156 and theenclosed volume 32 under the dressing 14. Reduced pressure is therefore developed in theenclosed volume 32. - With reference to
FIG. 10 , theelectrolyte solution 52 can be injected into thesubstrate 54 or mass of powdered chemicals making up the reducingagent 50 through thechemical pump housing 150 when reduced pressure therapy is ready to be administered. Aninjection port 192 can be disposed on thechemical pump housing 150 for guiding a user for injecting theneedle 94 of thesyringe 90 into thesubstrate 54 or mass of powdered chemicals making up the reducingagent 50. When reduced pressure is ready to be administered, the user injects theelectrolyte solution 52 into thesubstrate 54 to impregnate thesubstrate 54 with theelectrolyte solution 52 or into the mass of powdered chemicals making up the reducingagent 50. Once the reducingagent 50 is wetted with theelectrolyte solution 52, thereactor 16 begins to consume the selected gas in theenclosed volume 32 and theinner chamber 156 of thechemical pump housing 150. After finishing injecting theelectrolyte solution 52 into the dressing 14, theinjection port 92 can be covered with thethin film 182 and theflap 184 in a similar manner to theslit 170 shown inFIG. 9 . Also, theelectrolyte solution 52 stored in theflexible chamber 130 shown inFIG. 6 can deliver theelectrolyte solution 52 through theinjection port 192 in thechemical pump housing 150 similar to thesyringe 90. - Unlike solutions that package a reactor in a hermitically sealed foil packet, the electrolyte solution is shielded from the reducing agent until reduced pressure therapy of the dressing. It will be appreciated that various of the above-disclosed embodiments and other features and functions, or alternatives or varieties thereof, may be desirably combined into many other different systems or applications. Also that various presently unforeseen or unanticipated alternatives, modifications, variations or improvements therein may be subsequently made by those skilled in the art which are also intended to be encompassed by the following claims.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/709,561 US20220218529A1 (en) | 2019-10-03 | 2022-03-31 | Reduced pressure device having selectively deliverable electrolyte |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/592,142 US10881553B1 (en) | 2019-10-03 | 2019-10-03 | Reduced pressure device having selectively deliverable electrolyte |
PCT/US2020/053380 WO2021067340A1 (en) | 2019-10-03 | 2020-09-30 | Reduced pressure device having selectively deliverable electrolyte |
US17/709,561 US20220218529A1 (en) | 2019-10-03 | 2022-03-31 | Reduced pressure device having selectively deliverable electrolyte |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/053380 Continuation WO2021067340A1 (en) | 2019-10-03 | 2020-09-30 | Reduced pressure device having selectively deliverable electrolyte |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220218529A1 true US20220218529A1 (en) | 2022-07-14 |
Family
ID=74044911
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/592,142 Active US10881553B1 (en) | 2019-10-03 | 2019-10-03 | Reduced pressure device having selectively deliverable electrolyte |
US17/709,561 Pending US20220218529A1 (en) | 2019-10-03 | 2022-03-31 | Reduced pressure device having selectively deliverable electrolyte |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/592,142 Active US10881553B1 (en) | 2019-10-03 | 2019-10-03 | Reduced pressure device having selectively deliverable electrolyte |
Country Status (3)
Country | Link |
---|---|
US (2) | US10881553B1 (en) |
EP (1) | EP4037723A4 (en) |
WO (1) | WO2021067340A1 (en) |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2157169A (en) * | 1937-09-27 | 1939-05-09 | Foster Ruth | Heat bag |
US3635567A (en) * | 1969-12-31 | 1972-01-18 | Thomas F Richardson Jr | Package and applicator unit |
US4559921A (en) * | 1982-11-05 | 1985-12-24 | Simon Benmussa | Self-heating receptacle |
FR2585336A1 (en) * | 1985-07-23 | 1987-01-30 | Doukan Jacques | FOOD TRAY COMPRISING AN EXOTHERMIC REACTION HEATING DEVICE OF TWO REACTIVE PRODUCTS |
GB9515807D0 (en) * | 1995-08-02 | 1995-10-04 | Cantwell Evelyna D | Topical hyperbaric bandage |
US6341602B1 (en) * | 1999-03-09 | 2002-01-29 | Fred Fulcher | Package for flameless heating and heater for the package |
US6890553B1 (en) | 1999-07-08 | 2005-05-10 | Johnson & Johnson Consumer Companies, Inc. | Exothermic topical delivery device |
US6547468B2 (en) * | 2001-06-22 | 2003-04-15 | The Procter & Gamble Company | Dosing reservoir |
FR2846635B1 (en) * | 2002-10-30 | 2005-07-01 | D Lab | SINGLE USE PACKAGING FOR A DOSE OF PRODUCT |
US7361184B2 (en) * | 2003-09-08 | 2008-04-22 | Joshi Ashok V | Device and method for wound therapy |
WO2005108524A2 (en) * | 2004-05-04 | 2005-11-17 | Candle Corporation Of America | Heater product, system and composition |
US7182739B2 (en) * | 2005-05-12 | 2007-02-27 | S.C. Johnson & Son, Inc. | Therapy patch |
US7779625B2 (en) * | 2006-05-11 | 2010-08-24 | Kalypto Medical, Inc. | Device and method for wound therapy |
CA2661282C (en) * | 2006-08-10 | 2012-03-27 | Rechargeable Battery Corporation | Oxygen activated heater and methods of manufacturing same |
US20090326622A1 (en) * | 2008-06-26 | 2009-12-31 | Johnson Kroy D | Customizable therapeutic article for applying heat to the body |
US9428318B2 (en) * | 2009-03-19 | 2016-08-30 | Forever Young International, Inc. | Pouch for internal mixture of segregated reactants and applications thereof |
US8702665B2 (en) * | 2010-04-16 | 2014-04-22 | Kci Licensing, Inc. | Reduced-pressure sources, systems, and methods employing a polymeric, porous, hydrophobic material |
IN2015DN02739A (en) | 2012-10-19 | 2015-09-04 | Rechargeable Battery Corp | |
US9447987B1 (en) * | 2013-05-01 | 2016-09-20 | Preco, Inc. | Variable air access films |
US9278796B2 (en) * | 2014-02-17 | 2016-03-08 | Sonoco Development, Inc. | Container having self-contained heater material |
US10449094B2 (en) * | 2015-10-30 | 2019-10-22 | Lorain County Community College Innovation Foundation | Wound therapy device and method |
US10046095B1 (en) * | 2017-04-04 | 2018-08-14 | Aatru Medical, LLC | Wound therapy device and method |
US10583229B2 (en) * | 2017-04-04 | 2020-03-10 | Aatru Medical, LLC | Negative pressure device and method |
IL254644B (en) | 2017-09-24 | 2021-06-30 | Reddress Ltd | Wound dressing device, assembly and method |
US20200330659A1 (en) | 2017-12-22 | 2020-10-22 | Aatru Medical, Inc. | Wound therapy device, shell for wound therapy device and wound therapy method |
-
2019
- 2019-10-03 US US16/592,142 patent/US10881553B1/en active Active
-
2020
- 2020-09-30 EP EP20872209.0A patent/EP4037723A4/en active Pending
- 2020-09-30 WO PCT/US2020/053380 patent/WO2021067340A1/en unknown
-
2022
- 2022-03-31 US US17/709,561 patent/US20220218529A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4037723A1 (en) | 2022-08-10 |
EP4037723A4 (en) | 2023-10-25 |
WO2021067340A1 (en) | 2021-04-08 |
US10881553B1 (en) | 2021-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102576263B1 (en) | Negative pressure device and method | |
EP3813751B1 (en) | Dressing | |
US10583229B2 (en) | Negative pressure device and method | |
US11759369B2 (en) | Negative pressure treatment including mechanical and chemical pump | |
US20220241489A1 (en) | Negative pressure device for articulating joint | |
US20210299347A1 (en) | Negative pressure device having oxygen scavenger and volume reduction | |
US20240042122A1 (en) | Negative pressure treatment including mechanical and chemical pump | |
US20110257610A1 (en) | Therapeutic Diffusion Wound Dressing and Filling Method | |
CA3127811A1 (en) | Chemical pump housing for negative pressure system | |
US10383985B2 (en) | Methods and apparatus for charging and evacuating a diffusion dressing | |
US10881553B1 (en) | Reduced pressure device having selectively deliverable electrolyte | |
WO2011119760A2 (en) | Therapeutic diffusion wound dressing and filling method | |
WO2023102186A1 (en) | Negative pressure dressing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AATRU MEDICAL, LLC, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ADVANCED DRESSING, LLC;REEL/FRAME:059487/0427 Effective date: 20210318 Owner name: ADVANCED DRESSING, LLC, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WOJCIECHOWSKI, TIMOTHY;BUAN, JOHN;LASH, THOMAS E.;AND OTHERS;REEL/FRAME:059487/0348 Effective date: 20190927 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |